# Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage

> **NCT00589290** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (actual)

## Conditions studied

- Thymoma
- Thymic Carcinoma

## Interventions

- **DRUG:** Belinostat (PDX101)

## Key facts

- **NCT ID:** NCT00589290
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2013-07
- **Final completion:** 2014-06
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00589290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00589290, "Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00589290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*